News

Barchart on MSN2d
What to Expect From Regeneron's Next Quarterly Earnings Report
With a market cap of $62.4 billion, Regeneron Pharmaceuticals, Inc. (REGN) discovers, invents, develops, manufactures, and ...
Regeneron Gets FDA Priority Review for Expanded Eylea HD Use
Regeneron Pharmaceuticals has won U.S. Food and Drug Administration priority review for its application seeking expanded approval of its Eylea HD eye drug.
Seeking Alpha1d
REGN Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals ... The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
Regeneron price target lowered to $150 from $170 at Canaccord
Canaccord analyst John Newman lowered the firm’s price target on Regeneron (REGN) to $150 from $170 and keeps a Hold rating on the shares. The ...
Regeneron price target lowered to $547 from $575 at BofA
BofA lowered the firm’s price target on Regeneron (REGN) to $547 from $575 and keeps an Underperform rating on the shares based on a lower ...
FDA Sets The Countdown: Regeneron's Eylea HD Could Be Headed For Major Expansion
FDA accepts Regeneron's sBLA for Eylea HD in RVO with priority review; QUASAR data supports monthly dosing, target action date set for August 2025.
6REGN : Assessing Regeneron Pharmaceuticals: Insights From 7 Financial...
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $831.43, with a high estimate of $1013.00 and a low estimate of $547.00. Highlighting a 8.86% ...
Regeneron Pharmaceuticals Inc. stock rises Friday, still underperforms market
Shares of Regeneron Pharmaceuticals Inc. REGN rose 1.43% to $554.18 Friday, on what proved to be an all-around great trading ...